Subcutaneous infliximab in inflammatory bowel disease: from pharmacokinetic principles to clinical practice
Switching to subcutaneous infliximab could soon become standard care for inflammatory bowel disease, potentially improving symptom control with steadier drug levels.
INTRODUCTION: Subcutaneous infliximab (CT-P13 SC) was developed to address the pronounced peak-to-trough fluctuations of intravenous dosing and the immunogenicity driven by sub-therapeutic troughs. Within five years, fully subcutaneous pathways, immunomodulator de-escalation guided by steady-state levels, and dosing informed by individual clearance are expected to move from research questions to standard practice.
What the study was
- Study design
- Review
- Population
- INTRODUCTION: Subcutaneous infliximab (CT-P13 SC) was developed to address the pronounced peak-to-tr
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Expert opinion on biological therapy
Why it surfaced
moderate relevance to watchlist
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.